Rimac Anthony M 4
4 · Sagimet Biosciences Inc. · Filed Jul 20, 2023
Insider Transaction Report
Form 4
Rimac Anthony M
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-07-18+242,142→ 242,142 totalExercise: $13.51Exp: 2033-04-19→ Series A Common Stock (242,142 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-07-18−242,142→ 0 totalExercise: $13.51Exp: 2033-04-19→ Common Stock (242,142 underlying)
Footnotes (2)
- [F1]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
- [F2]25% of the shares underlying this option shall vest and become exercisable on April 10, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.